Ratings PT Gudang Garam Tbk Deutsche Boerse AG

Equities

GGG

ID1000068604

Delayed Deutsche Boerse AG 02:04:56 2024-05-16 EDT 5-day change 1st Jan Change
0.995 EUR +1.02% Intraday chart for PT Gudang Garam Tbk +5.85% -9.55%

Strengths

  • The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
  • The company is one of the most undervalued, with an "enterprise value to sales" ratio at 324.5 for the 2024 fiscal year.
  • The company's share price in relation to its net book value makes it look relatively cheap.
  • The company has a low valuation given the cash flows generated by its activity.
  • The company is one of the best yield companies with high dividend expectations.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
  • The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Tobacco

1st Jan change Capi. Investor Rating ESG Refinitiv
-9.55% 2.25B -
+14.08% 78.75B
B-
-6.63% 64.01B
B
+20.77% 50.39B
A-
+3.68% 7.48B
A-
-13.41% 5.63B
A-
+6.75% 2.63B
C-
-32.16% 1.64B -
-19.01% 1.1B
D+
0.00% 1.03B - -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW